Valuation: Tenax Therapeutics, Inc.

Market Cap 98.52M 87.98M 81.28M 73.66M 138M 9.35B 140M 978M 387M 4.9B 370M 362M 15.45B P/E 2026 *
-1.18x
P/E 2027 * -1.15x
Enterprise Value -244M -218M -201M -182M -341M -23.17B -347M -2.42B -959M -12.14B -916M -897M -38.27B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.82%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Tenax Therapeutics, Inc.

1 day-2.27%
1 week+26.47%
Current month-8.99%
1 month-9.47%
3 months-88.25%
6 months-87.69%
Current year-85.89%
1 week 1.41
Extreme 1.41
1.84
1 month 1.36
Extreme 1.36
2
Current year 1.31
Extreme 1.31
19.4
1 year 1.31
Extreme 1.31
19.4
3 years 1.31
Extreme 1.31
61.2
5 years 1.31
Extreme 1.31
2,576
10 years 1.31
Extreme 1.31
84,800
Manager TitleAgeSince
Chief Executive Officer 52 2021-07-13
Director of Finance/CFO 58 2026-05-10
Chief Tech/Sci/R&D Officer - 2025-12-31
Director TitleAgeSince
Chairman 67 2021-05-31
Director/Board Member 76 2021-02-24
Director/Board Member 70 2021-02-24
Date Insider Type Main position Quantity % Market Cap. Importance
9/16/26 Buy

Director

53,000 0.1416%
9/15/26 Buy

Chief Executive Officer

4,850 0.0130%
9/11/26 Buy

Chief Financial Officer

5,675 0.0152%
Change 5-day change 1-year change 3-year change Capi.($)
-2.27%+26.47%-76.53%-92.70% 98.52M
+2.41%+0.29%+42.02%+71.57% 64.69B
-0.15%+7.50%+11.01%+73.48% 54.78B
+0.57%+4.60%+10.07%+92.86% 53.49B
+0.37%+4.67%+27.03%+52.07% 45.98B
-1.21%+2.32%+21.80%+123.81% 42.94B
-0.37%+5.07%+249.91%+918.74% 40.08B
+0.05%+0.21%+18.26%+58.53% 33.52B
-0.38%+5.68%+36.43%+27.54% 23.67B
+1.19%-4.98%+29.01%-0.65% 23.97B
Average +0.02%+4.82%+36.90%+132.52% 38.32B
Weighted average by Cap. +0.39%+2.74%+47.54%+158.51%

Financials

2026 *2027 *
Net sales - -
Net income -72.73M -64.95M -60M -54.38M -102M -6.9B -103M -722M -286M -3.62B -273M -267M -11.41B -84.06M -75.07M -69.35M -62.84M -118M -7.98B -120M -835M -330M -4.18B -315M -309M -13.18B
Net Debt -343M -306M -283M -256M -479M -32.52B -487M -3.4B -1.35B -17.04B -1.29B -1.26B -53.72B -10.2M -9.11M -8.41M -7.63M -14.27M -968M -14.5M -101M -40.09M -507M -38.28M -37.47M -1.6B
Projected Income Statement - Annual - Tenax Therapeutics, Inc.
Logo Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Employees
15
Date Price Change Volume
26-10-23 US$1.720 -2.27% 854,385
26-10-22 US$1.760 +7.98% 3,299,451
26-10-21 US$1.630 0.00% 2,353,313
26-10-20 US$1.630 +7.24% 1,459,076
26-10-19 US$1.520 +11.76% 2,584,383
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Tenax Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
1.720USD
Average target price
9.625USD
Spread / Average Target
+459.59%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Tenax Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. TENX Stock